Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2020 1
2021 0
Text availability
Article attribute
Article type
Publication date

Search Results

2 results
Results by year
Filters applied: . Clear all
Page 1
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic.
Veve MP, Wagner JL. Veve MP, et al. Pharmacotherapy. 2018 Sep;38(9):935-946. doi: 10.1002/phar.2166. Epub 2018 Aug 20. Pharmacotherapy. 2018. PMID: 30019769 Review.
Lefamulin was also shown to retain activity against multidrug-resistant Neisseria gonorrhoeae and Mycoplasma genitalium. ...This review discusses the pertinent bacterial spectrum of activity, preclinical and ongoing clinical data, and potential roles in therapy for lefa …
Lefamulin was also shown to retain activity against multidrug-resistant Neisseria gonorrhoeae and Mycoplasma genitalium. ...This revi …
Clinical Utility of Lefamulin: If Not Now, When?
Mercuro NJ, Veve MP. Mercuro NJ, et al. Curr Infect Dis Rep. 2020;22(9):25. doi: 10.1007/s11908-020-00732-z. Epub 2020 Jul 9. Curr Infect Dis Rep. 2020. PMID: 32834786 Free PMC article. Review.
This review discusses the pertinent spectrum and clinical data of lefamulin (Xenleta), with a focus on potential real-world use. RECENT FINDINGS: Lefamulin is a novel pleuromutilin antibiotic that obtained Food and Drug Administration labeling for community-acquired …
This review discusses the pertinent spectrum and clinical data of lefamulin (Xenleta), with a focus on potential real-world use. RECE …